Dow Jones
39.671,04 -201,95 (-0,51%) Nasdaq
16.801,54 -31,08 (-0,18%) Nikkei 225
38.913,48 +296,38 (+0,77%) EUR/USD
1,0832 +0,0005 (+0,04%) Bitcoin EUR
64.121,07 -457,73 (-0,71%) CMC Crypto 200
1.511,53 -14,89 (-0,98%)
Exagen Inc. (XGN)
Dopo ore:
| Chiusura precedente | 1,9000 |
| Aperto | 1,8900 |
| Denaro | 1,8400 x 100 |
| Domanda | 1,9200 x 100 |
| Min-Max giorno | 1,8001 - 1,9708 |
| Intervallo di 52 settimane | 1,3000 - 3,4710 |
| Volume | |
| Media Volume | 48.759 |
| Capitalizzazione | 33,01M |
| Beta (mensile su 5 anni) | 1,21 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,3400 |
| Prossima data utili | 05 ago 2024 - 09 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 6,00 |
GlobeNewswireExagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2023, being held November 10-15, 2023, at the San Diego Convention Center in San Diego, California. Below is the list of accepted abstracts, with links to each: Sunday, November 12, 2023 Poster Presentation | Presented by Doruk E
- GlobeNewswire
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, which takes place September 26-28, 2023, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen’s President and Chief Executive Officer and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in a panel discussion on Tuesday, September
- GlobeNewswire
Exagen Inc. Reports Strong Second Quarter 2023 Results
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023. Second Quarter Highlights: Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022.Recognized total revenue of $14.1 million for the second quarter, a 26% increase over the first quarter of 2023.Achieved gross margin of 54% in the six months ended J
